Precision BioSciences (NASDAQ:DTIL) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Earnings and Valuation
This table compares Precision BioSciences and Champions Oncology's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Precision BioSciences | $22.24 million | 23.43 | $-92,880,000.00 | ($1.91) | -4.77 |
| Champions Oncology | $32.12 million | 4.53 | $-1,980,000.00 | ($0.17) | -63.88 |
Champions Oncology has higher revenue and earnings than Precision BioSciences. Champions Oncology is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Precision BioSciences and Champions Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Precision BioSciences | 0 | 1 | 4 | 0 | 2.80 |
| Champions Oncology | 0 | 0 | 1 | 0 | 3.00 |
Precision BioSciences presently has a consensus target price of $20.00, suggesting a potential upside of 119.30%. Champions Oncology has a consensus target price of $16.00, suggesting a potential upside of 47.33%. Given Precision BioSciences' higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than Champions Oncology.
Insider & Institutional Ownership
48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 52.8% of Champions Oncology shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by insiders. Comparatively, 46.8% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Precision BioSciences and Champions Oncology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Precision BioSciences | -484.81% | -105.74% | -53.08% |
| Champions Oncology | -4.18% | -29.93% | -7.41% |
Volatility & Risk
Precision BioSciences has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Summary
Champions Oncology beats Precision BioSciences on 9 of the 14 factors compared between the two stocks.
